Kaposi's sarcoma in renal transplantation: Report of three cases

Clinical Nephrology

Volumn 71, Issue 2, 2009, Pages 214-216

  Razeghi, E ^a   Hadadi, A ^a   Khashayar, P ^a   Pourmand, G ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CMV infection; Kaposi's sarcoma; Transplant

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PP65 ANTIGEN; PREDNISOLONE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANEMIA; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GRAFT RECIPIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MALE; OPPORTUNISTIC INFECTION; POSTOPERATIVE PERIOD; PURPURA; SKIN BIOPSY; SKIN DEFECT; THROMBOCYTOPENIA; WEAKNESS; MIDDLE AGED; RISK FACTOR;

ADULT; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; SARCOMA, KAPOSI;

EID: 64549164193     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71214     Document Type: Article

References (12)

1. Bedan PL, Risichella IS, strumia R et al. Kaposis sarcoma in renal transplant recipients: pathogenetic relation between the reduced density of Langerhans cells and cyclosporine therapy. J Nephrol. 1999; 12: 193-195.
2. Boubenider S, Hiesse C, Goupy C et al. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997; 10: 136-145.
3. Brunner FP, Landis P, Selwood AH. Malignancies after renal transplantation: The EDTA-ERA registry experience European Dialysis and Transplantation Association - Europeran Renal Association. Nephrol Dial Transplant. 1995;1 (Suppl 1): 74-80.
4. Chakalarouski C, Lang P, Buisson C et al. Monoclonal immunoglobulins in patients with renal transplants: characterization evolution and risk factors. Transpl Int. 1992; 5 (Suppl 1): 23-25.
5. Itkura H, Toriyama K, Uzuta F et al. Kaposis sarcoma. Gan to Kagaku Ryobo. 1990; 17: 620-626.
6. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipient American society of transplantation. JAM Soc Nephrol 2000; II (Suppl 15): 51-86.
7. London NJ, Farmery SM, Will EJ et al. Risk of neoplasia, in renal transplant patients. Lancet 1995; 346: 403-406.
8. Moosa MR. Kaposis Sarcoma in kidney transplant recipients: a 23-year experience. QKM. 2005; 98: 205-214.
9. Penn I. Neoplasms in renal transplant recipients. In: Massry SG, Glassock RJ (eds.) Massry and Glassocks textbook of nephrology, 4th edition. Philadelphia: Lippincott Williams Wilkins; 2001. pp. 1672-1677.
10. Regumey N, Tamm M, Wemli M et al. Transmission of human herpes virus and infections from renal transplant donors to recipients. N Engl J Med. 1998; 339: 1358-1368.
11. Seigal B, Levinton-Kriss S, Schiffer A et al. Kaposi sarcoma in immunosuppression. Possibly the result of a dual viral infection. Cancer. 1990; 65: 492-498.
12. Vlasic-Matas J, Rumboldt Z, Puizina-Ivic N et al. Kaposi sarcoma in patients with kidney transplantation. Lijec Vjesn. 1994; 116: 95-97.